Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers

McBride, B., Mogg, A., Telfer, J. L., Lever, M. S., Miller, J., Turnbull, P. C. B. and Baillie, Les ORCID: https://orcid.org/0000-0002-8186-223X 1998. Protective efficacy of a recombinant protective antigen against Bacillus anthracis challenge and assessment of immunological markers. Vaccine 16 (8) , pp. 810-817. 10.1016/S0264-410X(97)00268-5

Full text not available from this repository.

Abstract

The efficacy of recombinant Bacillus anthracis Protective Antigen (rPA) produced in Bacillus subtilis and formulated in Alhydrogel or MPL-TDM-CWS (Ribi adjuvant) has been tested and compared to the licensed UK human vaccine in guinea pigs challenged by the aerosol route with the Ames strain of B. anthracis. rPA combined with the Ribi adjuvant was found to be only formulation to provide 100% protection from challenge. Analysis of immunological parameters in the individual animals revealed significant differences between the View the MathML source vaccine group and rPA/Alhydrogel and human vaccine groups for antigen specific lymphocyte proliferation, PA neutralisation and antigen specific IgG2 levels, but indicated no significant differences in PA-specific IgG1 levels. rPA formulated in Alhydrogel induced a mainly IgG1 response whilst the View the MathML source vaccine produced a predominantly IgG2 response.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Pharmacy
Subjects:	R Medicine > RM Therapeutics. Pharmacology
Uncontrolled Keywords:	anthrax; vaccine efficacy; immunological markers
Publisher:	Elsevier
ISSN:	0264-410X
Last Modified:	18 Oct 2022 14:26
URI:	https://orca.cardiff.ac.uk/id/eprint/17499

Citation Data

Cited 93 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item